Cargando…

1175. Pulmonary Aspergillosis in Critically Ill Patients with COVID-19: A Case Series

BACKGROUND: Invasive pulmonary aspergillosis (IPA) has been reported in critically ill patients without pre-existing immunocompromising conditions. However, there are scant data on pulmonary aspergillosis in patients with COVID-19. METHODS: We performed a retrospective review of pharmacy records of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitaka, Hayato, Perlman, David C, Javaid, Waleed, Salomon, Nadim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776731/
http://dx.doi.org/10.1093/ofid/ofaa439.1361
_version_ 1783630750523850752
author Mitaka, Hayato
Perlman, David C
Javaid, Waleed
Salomon, Nadim
author_facet Mitaka, Hayato
Perlman, David C
Javaid, Waleed
Salomon, Nadim
author_sort Mitaka, Hayato
collection PubMed
description BACKGROUND: Invasive pulmonary aspergillosis (IPA) has been reported in critically ill patients without pre-existing immunocompromising conditions. However, there are scant data on pulmonary aspergillosis in patients with COVID-19. METHODS: We performed a retrospective review of pharmacy records of antifungal use during 3/21-4/22, 2020, and collect longitudinal clinical data. Cases were then classified by the clinical algorithm for IPA in the ICU (AspICU). RESULTS: 7 out of 18 (39%) patients who received antifungal therapy had Aspergillus fumigatus in tracheal aspirate specimens while mechanically ventilated in the ICU. None of the patients had EORTC/MSG host factors. Median time from admission to the date of positive respiratory culture was 9 days (range: 2-15). High-dose glucocorticoids were started a mean of 5.6 days (range 3-8) before the positive respiratory culture in 5 and on the day of the culture in 2. Six received 583-1000 mg equivalent of prednisone. Two received Tocilizumab. By AspICU criteria, 4 had putative IPA. Radiographic abnormalities included cavitary pneumonia, opacities with dense consolidation, worsening infiltrates, and diffuse interstitial and patchy hazy opacities. Compatible signs included worsening respiratory failure in 3 and fever after 3 days of antibacterial agents in 1. Associated findings were leukocytosis in 4, > 1 positive cultures in 3, high procalcitonin in 2, and positive serum galactomannan in 1. The remaining three were classified as colonization as they lacked compatible signs. One had concomitant Klebsiella aerogenes pneumonia with bacteremia, and two later developed Candidemia and Stenotrophomonas maltophilia pneumonia, respectively. All 3 had fever with leukocytosis. One had elevated procalcitonin. Six received antifungal therapy; one did not due to goals of care. All 7 patients expired despite ICU care. CONCLUSION: The critically ill patients with severe COVID-19 in whom respiratory culture grew Aspergillus fumigatus showed very high mortality despite antifungal treatment. By AspICU algorithm, 4 patients had putative IPA. Further data on risk factors and clinical predictors of IPA in COVID-19 are needed. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-7776731
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77767312021-01-07 1175. Pulmonary Aspergillosis in Critically Ill Patients with COVID-19: A Case Series Mitaka, Hayato Perlman, David C Javaid, Waleed Salomon, Nadim Open Forum Infect Dis Poster Abstracts BACKGROUND: Invasive pulmonary aspergillosis (IPA) has been reported in critically ill patients without pre-existing immunocompromising conditions. However, there are scant data on pulmonary aspergillosis in patients with COVID-19. METHODS: We performed a retrospective review of pharmacy records of antifungal use during 3/21-4/22, 2020, and collect longitudinal clinical data. Cases were then classified by the clinical algorithm for IPA in the ICU (AspICU). RESULTS: 7 out of 18 (39%) patients who received antifungal therapy had Aspergillus fumigatus in tracheal aspirate specimens while mechanically ventilated in the ICU. None of the patients had EORTC/MSG host factors. Median time from admission to the date of positive respiratory culture was 9 days (range: 2-15). High-dose glucocorticoids were started a mean of 5.6 days (range 3-8) before the positive respiratory culture in 5 and on the day of the culture in 2. Six received 583-1000 mg equivalent of prednisone. Two received Tocilizumab. By AspICU criteria, 4 had putative IPA. Radiographic abnormalities included cavitary pneumonia, opacities with dense consolidation, worsening infiltrates, and diffuse interstitial and patchy hazy opacities. Compatible signs included worsening respiratory failure in 3 and fever after 3 days of antibacterial agents in 1. Associated findings were leukocytosis in 4, > 1 positive cultures in 3, high procalcitonin in 2, and positive serum galactomannan in 1. The remaining three were classified as colonization as they lacked compatible signs. One had concomitant Klebsiella aerogenes pneumonia with bacteremia, and two later developed Candidemia and Stenotrophomonas maltophilia pneumonia, respectively. All 3 had fever with leukocytosis. One had elevated procalcitonin. Six received antifungal therapy; one did not due to goals of care. All 7 patients expired despite ICU care. CONCLUSION: The critically ill patients with severe COVID-19 in whom respiratory culture grew Aspergillus fumigatus showed very high mortality despite antifungal treatment. By AspICU algorithm, 4 patients had putative IPA. Further data on risk factors and clinical predictors of IPA in COVID-19 are needed. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2020-12-31 /pmc/articles/PMC7776731/ http://dx.doi.org/10.1093/ofid/ofaa439.1361 Text en © The Author 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Poster Abstracts
Mitaka, Hayato
Perlman, David C
Javaid, Waleed
Salomon, Nadim
1175. Pulmonary Aspergillosis in Critically Ill Patients with COVID-19: A Case Series
title 1175. Pulmonary Aspergillosis in Critically Ill Patients with COVID-19: A Case Series
title_full 1175. Pulmonary Aspergillosis in Critically Ill Patients with COVID-19: A Case Series
title_fullStr 1175. Pulmonary Aspergillosis in Critically Ill Patients with COVID-19: A Case Series
title_full_unstemmed 1175. Pulmonary Aspergillosis in Critically Ill Patients with COVID-19: A Case Series
title_short 1175. Pulmonary Aspergillosis in Critically Ill Patients with COVID-19: A Case Series
title_sort 1175. pulmonary aspergillosis in critically ill patients with covid-19: a case series
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776731/
http://dx.doi.org/10.1093/ofid/ofaa439.1361
work_keys_str_mv AT mitakahayato 1175pulmonaryaspergillosisincriticallyillpatientswithcovid19acaseseries
AT perlmandavidc 1175pulmonaryaspergillosisincriticallyillpatientswithcovid19acaseseries
AT javaidwaleed 1175pulmonaryaspergillosisincriticallyillpatientswithcovid19acaseseries
AT salomonnadim 1175pulmonaryaspergillosisincriticallyillpatientswithcovid19acaseseries